Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Opus Genetics, Inc.

NASDAQ: IRD · Life Sciences · 10 alerts · CIK 1228627

Share price
$4.04Close, Nov 16
Market cap
$390M
Shares outstanding
96.65MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Opus Genetics, Inc. filings on SEC EDGAR ↗

4:05 PM ET 10-Q
Financial Results

Opus Genetics Q3 2026 Results: Net Loss of $46.5M, Loss Widens

Opus Genetics reported a significant increase in net loss to $120.1 million for the nine months ended September 30, 2026, primarily driven by a $72.8 million fair value change in financial instruments. Despite the loss, the company strengthened its balance sheet through $82.9 million in financing activities, including a note purchase agreement and Series B preferred stock issuance, ending the period with $89.0 million in cash and cash equivalents.

Key figure
Net loss $46.5M
7:02 AM ET 8-K
Financial Results

Opus Genetics Financial Results

Opus Genetics reported financial results for the third quarter of 2026, highlighting a cash runway extending into 2029. The company achieved several clinical milestones, including full enrollment of its OPGx-LCA5 Phase 3 trial and FDA clearance of the IND for OPGx-RDH12. Additionally, the FDA approval of RYZUMVI for presbyopia triggered a regulatory milestone payment to the company.

Term
Q3 2026

“The last several months have marked a period of tremendous advancement for our leading gene therapy programs. Positive Cohort 1 data from our Phase 1/2 trial of OPGx-BEST1 provide important evidence of its potential to improve both visual function and retinal structure in patients with BEST1-related retinal disease.”

George Magrath, M.D., Chief Executive Officer of Opus Genetics

“The FDA approval of phentolamine ophthalmic solution 0.75% for presbyopia marks the second FDA-approved indication for RYZUMVI®, demonstrating the capabilities of our clinical and regulatory teams. With our cash runway into 2029, we remain focused on bringing potentially transformative gene therapies to patients with rare inherited retinal diseases.”

George Magrath, M.D., Chief Executive Officer of Opus Genetics

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.